Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Early Idiopathic Pulmonary Fibrosis
NCT00768300Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2008
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of ambrisentan in idiopathic pulmonary fibrosis (IPF), sponsored by Gilead Sciences. Started Dec 2008; status: terminated.
02
Drugs
ambrisentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00768300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768300.